USPTO Examiner CHERNYSHEV OLGA N - Art Unit 1675

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19091464NERVE GROWTH FACTOR AND METHODS OF USE THEREOF FOR NEURODEVELOPMENTAL DISABILITIES ASSOCIATED WITH NEONATAL HYPOXIC-ISCHEMIC ENCEPHALOPATHYMarch 2025February 2026Allow1120YesNo
18996523PROTEIN ANTIGEN COMBINATION FOR DETECTION OF ALZHEIMER'S DISEASE AND APPLICATION THEREOFJanuary 2025February 2026Allow1320NoNo
18953476METHODS FOR PREVENTING AND TREATING BRAIN INFLAMMATIONNovember 2024November 2025Allow1130YesNo
18763515DIAGNOSING MILD COGNITIVE IMPAIRMENT (MCI), PREDICTING ALZHEIMER'S DISEASE (AD) DEMENTIA ONSET, AND SCREENING AND MONITORING AGENTS FOR TREATING MCI OR PREVENTING DEMENTIA ONSETJuly 2024December 2025Allow1810YesNo
18735006METHODS AND COMPOSITIONS FOR DIAGNOSING BRAIN INJURY OR NEURODEGENERATIONJune 2024October 2025Allow1710YesNo
18646957GENE THERAPIES FOR LYSOSOMAL DISORDERSApril 2024September 2025Allow1720YesNo
18640030NOVEL BIOMARKERS AND METHODS FOR DIAGNOSING AND EVALUATING TRAUMATIC BRAIN INJURYApril 2024August 2025Abandon1610NoNo
18609247TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIESMarch 2024September 2024Allow610NoNo
18609223ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIESMarch 2024September 2024Allow610NoNo
18607723METHODS OF TREATING PRADER-WILLI SYNDROMEMarch 2024August 2025Abandon1710NoNo
18600801COMPOSITIONS AND METHODS FOR DISSOLVING PROTEIN AGGREGATESMarch 2024June 2025Allow1520NoNo
18596310ALPHA-SYNUCLEIN DETECTION USING BEADSMarch 2024July 2025Allow1620NoNo
18588150METHODS FOR AIDING IN DIAGNOSING AND EVALUATING A MILD TRAUMATIC BRAIN INJURY IN A HUMAN SUBJECT USING CARDIAC TROPONIN I AND EARLY BIOMARKERSFebruary 2024August 2025Abandon1810NoNo
18417630COMPOSITIONS AND METHODS OF MUSCLE SPECIFIC KINASE CHIMERIC AUTOANTIBODY RECEPTOR CELLSJanuary 2024January 2026Allow2420NoNo
18395097PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES COMPRISING COX2 ACETYLATING AGENT AS ACTIVE INGREDIENTDecember 2023June 2025Allow1820NoNo
18529720DELTA-2-TUBULIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR PERIPHERAL NEUROPATHYDecember 2023March 2026Allow2721NoNo
18513394SEPTAPEPTIDES ASSOCIATED WITH NEURODEGENERACYNovember 2023July 2025Abandon2001NoNo
18512323METHOD OF SCREENING COMPOUNDS FOR TREATING CNS DISORDERSNovember 2023November 2025Abandon2420NoNo
18509866DETECTION OF PATHOLOGICAL PROTEIN AGGREGATIONNovember 2023October 2025Allow2320YesNo
18486417METHOD OF IDENTIFYING MALODOR MODULATING COMPOUNDSOctober 2023November 2025Abandon2511NoNo
18475838COMPOSITIONS AND METHODS FOR TREATING NON-HEMORRHAGIC CLOSED HEAD INJURYSeptember 2023August 2024Allow1120NoNo
18306992ERYTHROCYTE-DERIVED EXTRACELLULAR VESICLES AND PROTEINS ASSOCIATED WITH SUCH VESICLES AS BIOMARKERS FOR PARKINSON'S DISEASESeptember 2023May 2025Allow2410NoNo
18460055METHODS OF TREATING PRADER WILLI SYNDROME AND CONDITIONS ASSOCIATED WITH LOW BASAL METABOLIC RATE OR HYPERPHAGIA USING A KATP CHANNEL OPENERSeptember 2023February 2026Allow3030YesYes
18447290BLOOD BIOMARKER THAT PREDICTS PERSISTENT COGNITIVE DYSFUNCTION AFTER CONCUSSIONAugust 2023May 2025Allow2220NoNo
18347108INNATE IMMUNE PROTEINS AS BIOMARKERS FOR CNS INJURYJuly 2023October 2025Allow2821NoNo
18206133METHODS OF DIAGNOSING ALZHEIMER'S DISEASE AND RISK OF PROGRESSION TO ALZHEIMER'S DISEASEJune 2023September 2025Allow2820NoNo
18327243METHOD OF TREATING LARGE VESSEL OCCLUSION STROKEJune 2023December 2025Allow3020NoNo
18195170Methods of Identifying Schizophrenia Patients At Risk for RelapseMay 2023August 2025Abandon2720NoNo
18313792METHODS OF TREATING AL AMYLOIDOSISMay 2023January 2025Allow2010NoNo
18310381SEROLOGIC ASSAY FOR SILENT BRAIN ISCHEMIAMay 2023November 2025Abandon3021YesNo
18300535p53 Peptides as Markers in the Diagnosis and Prognosis of Alzheimer's DiseaseApril 2023February 2025Abandon2201NoNo
18298953ANTIBODY-PEPTIDE FUSION PROTEINS FOR TREATING AMYLOID DISORDERSApril 2023September 2024Allow1721NoNo
18297883METHODS FOR DIAGNOSING HUNTINGTON’S DISEASEApril 2023April 2025Allow2420NoNo
18182822TREATMENT OF MOST BOTHERSOME SYMPTOM (MBS) ASSOCIATED WITH MIGRAINE USING ANTI-CGRP ANTIBODIESMarch 2023March 2025Allow2420NoNo
18173116ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIESFebruary 2023March 2025Allow2410YesNo
18173124TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIESFebruary 2023March 2025Allow2410YesNo
18111172TREATING REFRACTORY MIGRAINEFebruary 2023July 2024Allow1720NoNo
18102852BIOMARKERS AND METHODS FOR DETECTION OF SEIZURES AND EPILEPSYJanuary 2023June 2025Abandon2820NoNo
18095660HEXOKINASE 2-SPECIFIC INHIBITORS FOR USE IN ACUTE CENTRAL NERVOUS SYSTEM INJURYJanuary 2023January 2025Allow2520NoNo
18150377OPTIMIZED MINI-DYSTROPHIN GENES AND EXPRESSION CASSETTES AND THEIR USEJanuary 2023November 2024Allow2210NoNo
18069838ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH TAILORED AFFINITYDecember 2022November 2024Allow2310NoNo
17924622GLUTATHIONE TRISULFIDE (GSSSG) IN NEUROPROTECTIONNovember 2022December 2025Allow3710NoNo
17982769MULTI-PROTEIN BIOMARKER ASSAY FOR BRAIN INJURY DETECTION AND OUTCOMENovember 2022February 2025Allow2811NoNo
17971081IMMOBILIZED PROTEIN SYSTEM FOR RAPID AND ENHANCED MULTIPLEXED DIAGNOSTICSOctober 2022February 2025Abandon2801NoNo
17937339PATHOLOGIC TDP-43 AS A BIOMARKER FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHYSeptember 2022March 2026Allow4221YesNo
17912776RET (REARRANGED DURING TRANSFECTION) FOR THE ASSESSMENT OF STROKESeptember 2022February 2026Abandon4110NoNo
17876923LACTOFERRIN FOR USE IN THE DIAGNOSIS OR PROGNOSIS OF ALZHEIMER'S DISEASE, OR IN THE DIAGNOSIS OF PARKINSON'S DISEASEJuly 2022January 2025Abandon3001NoNo
17814486BLOOD-BASED DIAGNOSTIC ASSAYS FOR ALZHEIMER'S DISEASEJuly 2022January 2026Abandon4201NoNo
17791625NPTN65 IS A NEW TARGET FOR THE TREATMENT OF TAUOPATHIESJuly 2022December 2025Abandon4110NoNo
17788445Predictive Markers of PsychosisJune 2022January 2026Abandon4201NoNo
17757939METHOD FOR COLLECTING EXTRACELLULAR VESICLES DERIVED FROM NERVOUS SYSTEM CELLSJune 2022February 2026Allow4421YesNo
17845021INHIBITION OF AUTISM SPECTRUM DISORDER USING DECOY ANTIGENS TO MATERNAL BRAIN-REACTIVE ANTIBODIESJune 2022April 2025Allow3421NoNo
17839669METHODS OF DIAGNOSING OR AIDING IN DIAGNOSIS OF BRAIN INJURY CAUSED BY ACOUSTIC ENERGY, ELECTROMAGNETIC ENERGY, AN OVER PRESSURIZATION WAVE, AND/OR BLAST WINDJune 2022March 2026Abandon4511NoNo
17836475COMPOSITIONS FOR RESTORING GENE EXPRESSION IN NEUROPSYCHIATRIC OR NEURODEGENERATIVE DISORDERSJune 2022March 2026Allow4540YesNo
17831619MUTANT PROTEINS AND METHODS FOR THEIR PRODUCTIONJune 2022May 2025Abandon3511NoNo
17827933BIOMARKER FOR ALZHEIMER'S DISEASEMay 2022December 2025Abandon4310NoNo
17751704Memory in subjects with mini-mental state examination of 24-26May 2022December 2024Allow3121YesNo
17776391GAMMA-SECRETASE STABILIZING COMPOUND SCREENING ASSAYMay 2022December 2025Abandon4301NoNo
17734821METHODS AND COMPOSITIONS FOR THE IMPROVEMENT OF LYSOSOMAL FUNCTION AND TREATMENT OF NEURODEGENERATIVE DISEASEMay 2022January 2025Abandon3301NoNo
17731185METHODS FOR THE PREDICTION, PROGNOSIS, AND/OR DIAGNOSIS OF AN INFLAMMATORY RESPONSE ASSOCIATED WITH SCHIZOPHRENIAApril 2022January 2026Allow4410YesNo
17726367ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOFApril 2022January 2026Abandon4531NoNo
17724168Alpha-Synuclein mutants and uses thereofApril 2022January 2026Allow4521NoNo
17718789PEPTIDEApril 2022January 2025Allow3310NoNo
17637700ASSAYS FOR DETECTING AND QUANTIFYING A BIOMARKER OF PERICYTE INJURYFebruary 2022December 2025Abandon4511NoNo
17649760SCREENING METHODFebruary 2022December 2024Abandon3410NoNo
17647289ASTROCYTE TRAUMATOME AND NEUROTRAUMA BIOMARKERSJanuary 2022February 2025Allow3720NoNo
17569251SCREENING METHODS USING CANINE T2R RECEPTORS AND PET FOOD PRODUCTS AND COMPOSITIONS IDENTIFIED USING THE SAMEJanuary 2022January 2026Allow4941YesNo
17560297MARKERS AND THEIR USE IN BRAIN INJURYDecember 2021July 2025Allow4220NoNo
17556584METHODS FOR REDUCING POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD)December 2021February 2025Allow3820NoNo
17621189ANTI-CGRP RECEPTOR/ANTI-PAC1 RECEPTOR BISPECIFIC ANTIGEN BINDING PROTEINSDecember 2021March 2026Allow5021YesNo
17553173METHODS FOR DIAGNOSING ALZHEIMER'S DISEASE AND OTHER NEUROLOGICAL DISORDERSDecember 2021July 2025Allow4321NoNo
17617504APOLIPOPROTEIN E FRAGMENTSDecember 2021October 2025Abandon4601NoNo
17610016METHODS AND COMPOSITIONS FOR INHIBITING ADAM8 BIOLOGICAL ACTIVITIESNovember 2021September 2025Abandon4610NoNo
17609995EVALUATING BIOMARKERS ALONG WITH ADVANCED MAGNETIC RESONANCE IMAGING PROCEDURES IN A HUMAN SUBJECT THAT HAS SUSTAINED OR MAY HAVE SUSTAINED A HEAD INJURYNovember 2021August 2025Abandon4612NoNo
17608220TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIESHEREOFNovember 2021December 2025Allow4920NoNo
17606982ALPHA-SYNUCLEIN ASSAYSOctober 2021November 2025Abandon4811YesNo
17594614CATECHOLAMINE CONCENTRATIONS IN A BLOOD SAMPLE AND ARTERIAL HYPERTENSION STATUS IN A SUBJECT FOR A DIFFERENTIAL DIAGNOSIS OF NEURODEGENERATIVE DISEASES INCLUDING ALZHEIMER'S DISEASEOctober 2021August 2025Abandon4610NoNo
17594648PCSK9 INHIBITORS FOR NEUROPATHYOctober 2021August 2025Abandon4601NoNo
17497776CIRCULATING BIOMARKER LEVELS FOR DIAGNOSIS AND RISK-STRATIFICATION OF TRAUMATIC BRAIN INJURYOctober 2021November 2024Allow3820NoNo
17485850Compositions and Methods for Uncoupling TrkB Receptor from PLC Gamma 1 for the Treatment of Epilepsy and Anxiety-Like DisorderSeptember 2021November 2024Abandon3811NoNo
17483047GPR156 Variants And Uses ThereofSeptember 2021October 2024Allow3721NoNo
17483517CD14 ANTAGONIST ANTIBODIES FOR TREATING NEURODEGENERATIVE DISEASESSeptember 2021January 2025Allow4020NoNo
17477687ANTI-TAUC3 ANTIBODIES AND USES THEREOFSeptember 2021July 2024Allow3410NoNo
17411511METHODS FOR AIDING IN DIAGNOSING AND EVALUATING A MILD TRAUMATIC BRAIN INJURY IN A HUMAN SUBJECT USING CARDIAC TROPONIN IAugust 2021August 2024Allow3620YesNo
17378401ANTIGENIC PEPTIDES AND USES THEREOF FOR DIAGNOSING AND TREATING AUTISMJuly 2021January 2026Allow5450YesNo
17366991ErbB2 SIGNALING AND NERVE REGENERATIONJuly 2021October 2024Allow4020NoNo
17346152METHODS AND SYSTEMS FOR IDENTIFYING MODULATORS OF PERVASIVE DEVELOPMENTAL DISORDERSJune 2021April 2025Abandon4630NoNo
17312445Cell Body Targeted SensorsJune 2021February 2025Allow4511NoNo
17316230METHODS FOR AIDING IN THE DIAGNOSIS AND DETERMINATION OF THE EXTENT OF TRAUMATIC BRAIN INJURY IN A HUMAN SUBJECT USING THE EARLY BIOMARKER UBIQUITIN CARBOXY-TERMINAL HYDROLASE L1May 2021April 2024Allow3520YesNo
17237314TEST METHOD FOR OLFACTORY MUCOSA OR OLFACTORY MUCUS IN MAMMALSApril 2021November 2025Abandon5540NoNo
17284220SCREENING METHOD FOR THERAPEUTIC DRUG OR PROPHYLACTIC DRUG FOR TAUOPATHY AND DIAGNOSTIC METHOD FOR TAUOPATHYApril 2021January 2025Abandon4511NoNo
17154966DISCRIMINATING PARKINSON'S DISEASE FROM MULTIPLE SYSTEM ATROPHY USING ALPHA-SYNUCLEIN PMCAJanuary 2021December 2024Allow4630YesNo
16973502MATERIALS AND METHODS FOR TREATING STRESS-RELATED DISORDERS AND CANCERDecember 2020November 2024Allow4711NoNo
17085677Treatment of Neurodegenerative Conditions by Disruption of RhesOctober 2020September 2025Allow5960YesNo
17046648BRAIN NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIESOctober 2020April 2025Allow5421NoNo
16978022ANTI-PHF-TAU ANTIBODIES AND USES THEREOFSeptember 2020October 2024Allow5030NoNo
16969835TAU SINGLE DOMAIN ANTIBODIESAugust 2020August 2024Allow4840YesNo
16968812Pulse Stable Tracer Methods for Detection of Short-Chain Fatty AcidsAugust 2020July 2025Allow5930NoNo
16651926METHODS FOR IDENTIFYING AND TREATING ADRENOMYELONEUROPATHY (AMN)March 2020December 2024Allow5722NoNo
16673767CHANNEL MODULATORSNovember 2019November 2024Abandon6041NoYes

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHERNYSHEV, OLGA N.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
7
Examiner Affirmed
2
(28.6%)
Examiner Reversed
5
(71.4%)
Reversal Percentile
88.4%
Higher than average

What This Means

With a 71.4% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
44
Allowed After Appeal Filing
19
(43.2%)
Not Allowed After Appeal Filing
25
(56.8%)
Filing Benefit Percentile
71.8%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 43.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner CHERNYSHEV, OLGA N - Prosecution Strategy Guide

Executive Summary

Examiner CHERNYSHEV, OLGA N works in Art Unit 1675 and has examined 226 patent applications in our dataset. With an allowance rate of 92.0%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.

Allowance Patterns

Examiner CHERNYSHEV, OLGA N's allowance rate of 92.0% places them in the 78% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by CHERNYSHEV, OLGA N receive 2.71 office actions before reaching final disposition. This places the examiner in the 80% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CHERNYSHEV, OLGA N is 38 months. This places the examiner in the 29% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +5.6% benefit to allowance rate for applications examined by CHERNYSHEV, OLGA N. This interview benefit is in the 32% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 24.8% of applications are subsequently allowed. This success rate is in the 37% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 49.4% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 70% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 82.1% of appeals filed. This is in the 75% percentile among all examiners. Of these withdrawals, 62.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 77.8% are granted (fully or in part). This grant rate is in the 83% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 20.4% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.8% of allowed cases (in the 77% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.